Total Brain Signs licencing deal with Alto Neuroscience
- Total Brain (TTB) has entered a perpetual, non-exclusive licencing deal with Alto Neuroscience
- Under the deal, TotalBrain will hand over its International Study to Predict Optimized Treatment for Depression (iSpot-D) research data to Alto
- TotalBrain will receive a one-off licence fee of US$500,000 (A$692,266) for handing over its data, with US$100,000 (A$138,453) payable by January 15
- The licence is subject to conventional commercial termination provisions and will come into effect immediately
- Shares in TotalBrain are up a healthy 27.3 per cent and are trading at 14 cents
